Drug intelligence / Profile preview

methylnaltrexone + codeine

Development stage
Unknown
Lead developer
Lantheus
Modality
Small Molecules
Administration
Oral, Subcutaneous, Intramuscular
01

Overview

Methylnaltrexone + codeine is a combination of two drugs with opposing actions on opioid receptors. Methylnaltrexone is a peripherally acting μ-opioid receptor antagonist, primarily used to treat opioid-induced constipation by blocking the effects of opioids like codeine in the gastrointestinal tract without affecting their pain-relieving properties in the central nervous system[1][3][4][5][6]. Codeine is an opioid analgesic that acts as an agonist at μ-opioid receptors to provide pain relief. When used together, this combination could theoretically allow for effective pain management with reduced risk of opioid-induced constipation, though such combinations are not standard clinical practice and may be considered investigational or off-label.

Brand names
Relistor (for methylnaltrexone)
Other names
MNTX (for methylnaltrexone)naltrexone-methyl-bromide (for methylnaltrexone)
02

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on methylnaltrexone + codeine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on methylnaltrexone + codeine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call